Paper Details

  1. Home
  2. Paper Details

Lamotrigine therapy for partial seizures: a multicenter, placebo-controlled, double-blind, cross-over trial.

Author: LeroyR F, MattsonR, MessenheimerJ, PellockJ M, RamsayR E, RisnerM, ValakasA M, WillmoreL J, WombleG, ZielinskiJ J

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Overview

This study evaluated the efficacy and safety of lamotrigine (LTG), a new antiepileptic drug (AED), in patients with refractory partial seizures. LTG significantly decreased seizure frequency and improved overall patient clinical status. Adverse experiences were generally minor and most frequently were CNS-related.
Paper Details　
Original Abstract of the Article :
The efficacy and safety of lamotrigine (LTG), a new antiepileptic drug (AED), were evaluated in a multicenter, randomized, double-blind, placebo-controlled, cross-over study of 98 patients with refractory partial seizures. Each treatment period lasted 14 weeks. Most patients were titrated to a LTG m...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1111/j.1528-1157.1994.tb02920.x

データ提供：米国国立医学図書館（NLM）

Lamotrigine: A New Path in the Desert of Epilepsy Treatment

Epilepsy, a challenging and often unpredictable condition, is like a vast and unforgiving desert for those who experience seizures. This multicenter, double-blind, cross-over trial, like a dedicated caravan seeking a cure, investigates the efficacy and safety of lamotrigine (LTG), a new antiepileptic drug (AED), for patients with refractory partial seizures. The researchers carefully design the study, randomly assigning patients to receive LTG or placebo over two 14-week periods, meticulously monitoring seizure frequency, overall clinical status, and adverse effects. This study's findings, like a well-preserved map, guide us through the potential benefits and risks of LTG for patients with refractory partial seizures.

A Glimpse into the Potential of Lamotrigine

The study's results, like a refreshing spring in the desert, demonstrate the effectiveness of LTG in reducing seizure frequency in patients with refractory partial seizures. While the drug did not completely eliminate seizures in all patients, it significantly reduced seizure frequency and improved overall clinical status. These findings offer a glimmer of hope for those seeking effective treatment for epilepsy.

Navigating the Desert of Epilepsy Treatment

This research highlights the importance of exploring new treatment options for epilepsy, particularly for those with refractory seizures. It emphasizes the need for careful monitoring and individualized treatment approaches, considering the potential risks and benefits of each medication. The desert of epilepsy research continues to evolve, and we must adapt our strategies to provide the most effective care for those living with this challenging condition.

Dr.Camel's Conclusion

This study provides valuable insights into the efficacy and safety of lamotrigine for patients with refractory partial seizures. It offers a promising treatment option and highlights the need for ongoing research and personalized approaches to managing this complex neurological condition.

Date :
  1. Date Completed 1994-03-25
  2. Date Revised 2019-08-13
Further Info :

Pubmed ID

8112232

DOI: Digital Object Identifier

10.1111/j.1528-1157.1994.tb02920.x

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.